Latest market price
172.95
-3.99-2.25%
RGENQT61Repligen Corporation·NASDAQ
172.95-2.25%
News
Down 2.3% — RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.21Insider Own0.99%Shs Outstand63.49MPerf Week-4.01%
Market Cap10.98BForward P/E64.92EPS next Y2.66Insider Trans-4.02%Shs Float53.72MPerf Month-4.82%
Enterprise Value10.79BPEG—EPS next Q0.53Short Float13.30%Perf Quarter15.47%
Income-12.00MP/S13.64EPS this Y24.59%Short Ratio5.86Perf Half Y46.31%
Sales805.00MP/B5.25EPS next Y28.50%ROA-0.40%Short Interest7.15MPerf YTD5.55%
Book/sh32.95P/C12.72EPS next 5Y28.11%ROE-0.56%52W High198.87 -13.03%Perf Year19.63%
Cash/sh13.59P/FCF103.59EPS past 3/5Y-35.73% -4.98%ROIC-0.96%52W Low100.99 71.25%Perf 3Y41.18%
Dividend Est.—EV/EBITDA85.63Sales past 3/5Y-2.73% 15.06%Gross Margin51.05%Volatility5.32% 5.04%Perf 5Y-37.03%
Dividend TTM—EV/Sales13.40EPS Y/Y TTM—Oper. Margin2.35%ATR (14)9.08Perf 10Y491.28%
Dividend Ex-Date—Quick Ratio8.43Sales Y/Y TTM13.70%Profit Margin-1.47%RSI (14)45.77Recom2.04
Dividend Gr. 3/5Y—Current Ratio9.88EPS Q/Q15.22%SMA20-2.17%Beta1.12Target Price188.67
Payout0.00%Debt/Eq0.32Sales Q/Q10.58%SMA50-2.78%Rel Volume1.32Prev Close176.94
Employees2,000LT Debt/Eq0.32EarningsFeb 23SMA20019.43%Avg Volume1.19MPrice172.95
IPO DateApr 29, 1986Option/ShortYes / YesEPS/Sales Surpr.14.51% 1.26%Net Debt/EBITDA-1.52Volume1,576,318Change-2.25%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-28-26ReiteratedRBC CapitalOutperform$160 → $200
Oct-19-26ReiteratedCanaccord GenuityHold$145 → $180
Oct-07-26ReiteratedBarclaysOverweight$145 → $225
Sep-09-26ReiteratedUBSBuy$200 → $225
Jul-07-26UpgradeBenchmarkHold → Buy
Jul-06-26ReiteratedEvercore ISI GroupOutperform$160
May-14-26ResumedRBC CapitalOutperform$205 → $160
May-05-26ReiteratedJefferiesHold$152 → $142
Apr-20-26ReiteratedCanaccord GenuityHold$165 → $145
Apr-17-26InitiatedRothschild & Co RedburnBuy$160
Latest News· Times ET
Oct-31-26
Oct-30-26
Oct-29-26
Oct-27-26
Oct-26-26
Oct-19-26
Oct-16-26
Oct-15-26
Oct-14-26
Oct-14-2611:57PM
Oct-13-26
Company

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue805738634632—————
Cost of Goods Sold Incl. D&A394391360354—————
Gross Profit410348275278—————
Selling, General and Administrative Excl. Other301291263219—————
Research and Development54544343—————
Other Operating Expense37-574-31—————
Operating Income1960-3548—————
Interest Expense1232310—————
Unusual Expense
—————————
Non-Operating Income (Expense)-11263119—————
Net Income Before Taxes862-2757—————
Income Taxes2013-221—————
Consolidated Net Income-1249-2636—————
Net Income From Continuing Operations-1249-2636—————
Net Income-1249-2636—————
EPS (Recurring)-0.210.87-0.460.64—————
EPS (Basic, Before Extraordinaries)-0.210.87-0.460.64—————
EPS (Diluted)-0.210.86-0.460.63—————
EBITDA12618380145—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—190.53—285.40—————
Price To Sales Ratio12.2512.4312.7115.93—————
Gross Margin50.9347.1543.3843.99—————
Operating Margin2.368.13-5.527.59—————
Net Margin-1.496.64-4.105.70—————
Shares Outstanding57565656—————
Market Capitalization9,8589,1768,06110,069—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$208.32$178.52$148.72$118.92$89.12● Close Price0.00M2.14M4.27M6.41M8.54MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Loeillot OlivierChief Executive OfficerOct 05 '26Option Exercise154.964,202651,14249,990Oct 06
Loeillot OlivierChief Executive OfficerOct 05 '26Sale187.295,5351,036,65445,788Oct 06
Loeillot OlivierChief Executive OfficerSep 24 '26Option Exercise155.1112,9462,008,02056,773Sep 25
Loeillot OlivierChief Executive OfficerSep 24 '26Sale190.004,542862,98048,369Sep 25
Loeillot OlivierChief Executive OfficerSep 21 '26Option Exercise141.795,426769,35353,795Sep 22
Loeillot OlivierChief Executive OfficerSep 21 '26Sale180.005,426976,68048,369Sep 22
Loeillot OlivierChief Executive OfficerSep 04 '26Sale165.903,035503,50748,369Sep 08
Loeillot OlivierChief Executive OfficerAug 20 '26Option Exercise141.795,426769,35359,672Aug 21
Loeillot OlivierChief Executive OfficerAug 20 '26Sale180.005,426976,68054,246Aug 21
Garland Jason KCFOJul 16 '26Sale150.0053079,50018,829Jul 17
Garland Jason KCFOJun 25 '26Sale145.00733106,28519,359Jun 26
MUIR GLENN PDirectorMay 07 '26Option Exercise38.764,868188,68439,056May 08
Loeillot OlivierChief Executive OfficerApr 21 '26Sale140.003,832536,48054,246Apr 22
DAWES KAREN ADirectorDec 17 '25Sale161.0027544,27591,821Dec 18
MUIR GLENN PDirectorDec 16 '25Option Exercise26.126,732175,84036,622Dec 17
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.